الفهرس 
Acute Myeloid LeukemiaOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
ABSTRACT
Background: acute myeloid leukemia (AML) is a malignant disorder of hematopoietic stem cells characterized by clonal expansion of abnormally differentiated blasts of myeloid lineage leading to impairment of normal hematopoiesis, leading to severe infections, anemia, and hemorrhage. Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment modality for AML. The choice of the conditioning regimens for HSCT is influenced by various factors, such as patient’s age, disease risk, performance status and remission status at the time of transplantation.
Aim of the work: This study investigates the outcome of conditioning regimen with Fludarabine and Busulfan in patients with AML who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) regarding transplant-related complications; disease-free survival (DFS); event free survival (EFS); overall survival (OS); relapse rate; as well as transplant related mortality.
Patients and Methods: this retrospective study included all patients with AML (Non-APL) AML in first complete remission (CR1), second complete remission (CR2) and CR3, who underwent allogeneic PBSCT from HLA identical family donor at Bone Marrow Transplantation Unit of Nasser Institute Hospital, in Egypt, during the period from 2006 to December 2016.
Results: engraftment was rapidly and successfully achieved in (94.87%) of patients, the mean time for neutrophils engraftment was 14.12 (± 3.26) days, and the mean time for platelet engraftment was 13.62 (± 5.5) days. Acute GVHD was observed in 30 patients (25.64%), while chronic GVHD was detected in 29 patients (24.78%). The Kaplan-Meier estimator probability at 10-years follow up for EFS was 49.6% (95% CI: 41.2% - 59.7%), for OS was 62% (95% CI: 53.6% -71.7%), and for DFS was 87.5% (95% CI: 79.7% -96.0%).
Conclusion: we conclude that myeloablative FLU/BU conditioning regimen for patients with AML is well tolerated, and associated with lower treatment related mortality, while retains a potent anti-leukemic activity represented by the low incidence rate of relapse.